

Dame Lesley Fallowfield

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7457276/dame-lesley-fallowfield-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

290
papers

27,131
citations

84
h-index

160
g-index

318
ext. papers

30,542
ext. citations

6.4
avg, IF

6.92
L-index

#	Paper	IF	Citations
290	IMPARTER, Phase 1 of an intervention to improve patients' understanding of gene expression profiling tests in breast cancer.. <i>Breast Cancer Research and Treatment</i> , 2022 , 192, 265	4.4	
289	The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline.. <i>Annals of Oncology</i> , 2022 ,	10.3	9
288	POSNOC-POSitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes. <i>BMJ Open</i> , 2021 , 11, e054365	3	4
287	UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysis. <i>Trials</i> , 2021 , 22, 173	2.8	1
286	A structured review of quality of life in advanced and high-risk cutaneous squamous cell carcinoma shows the need for more studies and better measures. <i>Skin Health and Disease</i> , 2021 , 1, e39		1
285	The Pulmonary Metastasectomy in Colorectal Cancer cohort study: Analysis of case selection, risk factors and survival in a prospective observational study of 512 patients. <i>Colorectal Disease</i> , 2021 , 23, 1793-1803	2.1	22
284	Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. <i>Lancet, The</i> , 2021 , 397, 2182-2193	40	68
283	Gaps in Care and Support for Patients With Advanced Breast Cancer: A Report From the Advanced Breast Cancer Global Alliance. <i>JCO Global Oncology</i> , 2021 , 7, 976-984	3.7	0
282	Pulmonary metastasectomy in colorectal cancer: health utility scores by EQ-5D-3L in a randomized controlled trial show no benefit from lung metastasectomy. <i>Colorectal Disease</i> , 2021 , 23, 200-205	2.1	17
281	An online review of informational sources for advanced or high-risk cutaneous squamous cell carcinoma. <i>Supportive Care in Cancer</i> , 2021 , 29, 4199-4207	3.9	0
280	Performance Characteristics of the Ultrasound Strategy during Incidence Screening in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Cancers</i> , 2021 , 13,	6.6	1
279	Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study. <i>European Journal of Cancer</i> , 2021 , 152, 223-232	7.5	4
278	The Prospective Observational Cohort and the Nested Randomized Controlled Trial in the Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC Study) Question the Reliance on Existing Evidence for the Magnitude of Benefit From Lung Metastasectomy. <i>American Journal of Clinical Oncology</i> , 2021 , 44, 500-503	2.7	1
277	The Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) burden of care study: Analysis of local treatments for lung metastases and systemic chemotherapy in 220 patients in the PulMiCC cohort. <i>Colorectal Disease</i> , 2021 , 23, 2911-2922	2.1	4
276	Enhancing your WebsideManner: communication during COVID-19. <i>Trends in Urology & Men's Health</i> , 2021 , 12, 12-15	0.3	2
275	Completeness and accuracy of national cancer and death registration for outcome ascertainment in trials-an ovarian cancer exemplar. <i>Trials</i> , 2021 , 22, 88	2.8	1
274	The fallacy of large survival gains from lung metastasectomy in colorectal cancer. <i>Lancet, The</i> , 2021 , 397, 97-98	40	1

273	Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives. <i>Supportive Care in Cancer</i> , 2020 , 28, 4589-4612	3.9	47
272	Ovarian cancer symptoms, routes to diagnosis and survival - Population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Gynecologic Oncology</i> , 2020 , 158, 316-322	4.9	3
271	A systematic review of communication interventions to help healthcare professionals discuss genetic testing for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020 , 183, 9-21	4.4	3
270	NICE Guidelines: management of colorectal cancer metastases. <i>British Journal of Surgery</i> , 2020 , 107, e357	5.3	7
269	Communicating the oncotype DX \square test results: A novel educational workshop for specialist breast care nurses. <i>European Journal of Oncology Nursing</i> , 2020 , 49, 101843	2.8	
268	5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). <i>Annals of Oncology</i> , 2020 , 31, 1623-1649	10.3	282
267	The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020 , 183, 629-638	4.4	1
266	Reply to 'Comment on "The myth of pulmonary metastasectomy"'. <i>British Journal of Cancer</i> , 2020 , 123, 1835-1836	8.7	
265	Using patient perspectives to inform communication training materials for health care professionals discussing BRCA mutation testing. <i>Breast Cancer Research and Treatment</i> , 2020 , 184, 491-498	4.4	2
264	The myth of pulmonary metastasectomy. <i>British Journal of Cancer</i> , 2020 , 123, 499-500	8.7	10
263	Current state of quality of life and patient-reported outcomes research. <i>European Journal of Cancer</i> , 2019 , 121, 55-63	7.5	41
262	Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. <i>Annals of Oncology</i> , 2019 , 30, 567-574	10.3	11
261	Talking about risk in the context of genomic tests (TARGET): development and evaluation of an educational program for clinicians. <i>Breast Cancer Research and Treatment</i> , 2019 , 177, 641-649	4.4	4
260	The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer. <i>Health Policy and Technology</i> , 2019 , 8, 75-83	4.8	2
259	Development and validation of the caregiver roles and responsibilities scale in cancer caregivers. <i>Quality of Life Research</i> , 2019 , 28, 1655-1668	3.7	5
258	Sexual functioning in 4,418 postmenopausal women participating in UKCTOCS: a qualitative free-text analysis. <i>Menopause</i> , 2019 , 26, 1100-1009	2.5	13
257	Pulmonary Metastasectomy versus Continued Active Monitoring in Colorectal Cancer (PulMiCC): a multicentre randomised clinical trial. <i>Trials</i> , 2019 , 20, 718	2.8	89
256	Treatment Experiences, Information Needs, Pain and Quality of Life in Men with Metastatic Castrate-resistant Prostate Cancer: Results from the EXTREQOL Study. <i>Clinical Oncology</i> , 2019 , 31, 99-107	2.8	6

255	Enhancing decision-making about adjuvant chemotherapy in early breast cancer following EndoPredict testing. <i>Psycho-Oncology</i> , 2018 , 27, 1264-1269	3.9	10
254	Development and validation of the patient roles and responsibilities scale in cancer patients. <i>Quality of Life Research</i> , 2018 , 27, 2923-2934	3.7	6
253	4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) <i>Annals of Oncology</i> , 2018 , 29, 1634-1657	10.3	645
252	RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018 , 27, 58-66	4	2
251	Do drugs offering only PFS maintain quality of life sufficiently from a patient's perspective? Results from AVALPROFS (Assessing the 'VALue' to patients of PROgression Free Survival) study. <i>Supportive Care in Cancer</i> , 2018 , 26, 3941-3949	3.9	5
250	3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). <i>Annals of Oncology</i> , 2017 , 28, 16-33	10.3	241
249	Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial. <i>Breast</i> , 2017 , 34, 89-95	3.6	13
248	The effect of ovarian cancer screening on sexual activity and functioning: results from the UK collaborative trial of ovarian cancer screening RCT. <i>British Journal of Cancer</i> , 2017 , 116, 1111-1117	8.7	6
247	3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). <i>Breast</i> , 2017 , 31, 244-259	3.6	137
246	Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits. <i>Supportive Care in Cancer</i> , 2017 , 25, 237-244	3.9	17
245	Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study. <i>European Journal of Cancer</i> , 2017 , 86, 82-90	7.5	33
244	Self-reported sexual health: Breast cancer survivors compared to women from the general population - an observational study. <i>BMC Cancer</i> , 2017 , 17, 599	4.8	28
243	Long-Term Follow-Up of the Intergroup Exemestane Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2507-2514	25.4	13
242	The pervasive nature of uncertainty-a qualitative study of patients with advanced cancer and their informal caregivers. <i>Journal of Cancer Survivorship</i> , 2017 , 11, 590-603	5.1	29
241	The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>British Journal of Cancer</i> , 2017 , 117, 619-627	8.7	19
240	A new paradigm or a misrepresentation of current communication research and teaching?. <i>Medical Education</i> , 2017 , 51, 1289-1290	3.7	2
239	Quality of survival: a new concept framework to assess the quality of prolonged life in cancer. <i>Expert Review of Quality of Life in Cancer Care</i> , 2017 , 2, 225-232		4
238	Patient-reported outcome measures of the impact of cancer on patients' everyday lives: a systematic review. <i>Journal of Cancer Survivorship</i> , 2017 , 11, 211-232	5.1	40

237	Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial. <i>Annals of Surgical Oncology</i> , 2017 , 24, 566-567	3.1	7
236	Patient/oncologist decisions about adjuvant chemotherapy in ER+ve, HER2-ve early breast cancer following endopredict testing.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e12002-e12002	2.2	3
235	Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. <i>Annals of Oncology</i> , 2016 , 27, 2046-2052	10.3	26
234	No man's land: information needs and resources of men with metastatic castrate resistant prostate cancer. <i>Supportive Care in Cancer</i> , 2016 , 24, 4471-3	3.9	5
233	Ovarian cancer. <i>Nature Reviews Disease Primers</i> , 2016 , 2, 16061	51.1	420
232	Overtreatment of Low-Grade Ductal Carcinoma In Situ. <i>JAMA Oncology</i> , 2016 , 2, 382-3	13.4	7
231	Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. <i>Lancet, The</i> , 2016 , 387, 945-956	40	563
230	Reply to P.F. Pinsky, C.P. Crum, and M.W. McIntosh et al. <i>Journal of Clinical Oncology</i> , 2016 , 34, 201-2	2.2	
229	Effects of Standard Treatments for Ductal Carcinoma In Situ-Making Informed Choices. <i>JAMA Oncology</i> , 2016 , 2, 396-7	13.4	6
228	Second international consensus guidelines for breast cancer in young women (BCY2). <i>Breast</i> , 2016 , 26, 87-99	3.6	84
227	Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. <i>Supportive Care in Cancer</i> , 2016 , 24, 1327-37	3.9	49
226	The Quality of Survival (QoS): A concept framework to assist communication and decision making about cancer care.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 78-78	2.2	1
225	Sexual Dysfunction in Breast Cancer Survivors: Cross-Cultural Adaptation of the Sexual Activity Questionnaire for Use in Portugal. <i>Acta Medica Portuguesa</i> , 2016 , 29, 533-541	1.4	1
224	Patient-reported outcomes in metastatic castration-resistant prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 643-50	19.4	20
223	Patient-reported outcome measures for cancer caregivers: a systematic review. <i>Quality of Life Research</i> , 2016 , 25, 1859-76	3.7	33
222	Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study. <i>Breast</i> , 2015 , 24, 166-70	3.6	14
221	Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents. <i>Supportive Care in Cancer</i> , 2015 , 23, 1157-68	3.9	27
220	Sexual activity and functioning in ovarian cancer survivors: an internet-based evaluation. <i>Climacteric</i> , 2015 , 18, 94-8	3.1	23

219	Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2062-71	2.2	133
218	Addressing overtreatment of screen detected DCIS; the LORIS trial. <i>European Journal of Cancer</i> , 2015 , 51, 2296-303	7.5	197
217	For the Benefit of Others: Reasons Why Women with Breast Cancer Participate in RCTs. <i>Breast Care</i> , 2015 , 10, 88-93	2.4	4
216	Psychosocial Factors Associated With Withdrawal From the United Kingdom Collaborative Trial of Ovarian Cancer Screening After 1 Episode of Repeat Screening. <i>International Journal of Gynecological Cancer</i> , 2015 , 25, 1519-25	3.5	9
215	Psychosocial/survivorship issues in breast cancer: are we doing better?. <i>Journal of the National Cancer Institute</i> , 2015 , 107, 335	9.7	70
214	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). <i>Breast</i> , 2014 , 23, 489-502	3.6	231
213	Low grade Ductal Carcinoma in situ (DCIS): how best to describe it?. <i>Breast</i> , 2014 , 23, 693-6	3.6	15
212	Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review. <i>Patient</i> , 2014 , 8, 145	3.7	63
211	The need to determine whether lung metastasectomy improves survival in advanced colorectal cancer. <i>BMJ, The</i> , 2014 , 348, g4085	5.9	6
210	Tumor boards: optimizing the structure and improving efficiency of multidisciplinary management of patients with cancer worldwide. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014 , e461-6	7.1	106
209	Words matter: distinguishing "personalized medicine" and "biologically personalized therapeutics". <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	18
208	Psychological morbidity associated with ovarian cancer screening: results from more than 23,000 women in the randomised trial of ovarian cancer screening (UKCTOCS). <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2014 , 121, 1071-9	3.7	30
207	Blurring of boundaries in the doctor-patient relationship. <i>Lancet Oncology, The</i> , 2014 , 15, 1423-1424	21.7	10
206	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) <i>Annals of Oncology</i> , 2014 , 25, 1871-1888	10.3	279
205	Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. <i>Annals of Oncology</i> , 2014 , 25, 1979-1987	10.3	101
204	Communication skills training for breast cancer teams talking about trials. <i>Breast</i> , 2014 , 23, 193-7	3.6	17
203	Denosumab or zoledronic acid (ZA) therapy on pain interference and cancer-specific quality of life (CSQoL) in patients with castrate-resistant prostate cancer (CRPC) and bone metastases (BM).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 12-12	2.2	5
202	What's in a name: Describing ductal carcinoma in situ (DCIS).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e12020-e12020		

201 Psychosocial issues in breast cancer **2014**, 258-267

200	Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. <i>Supportive Care in Cancer</i> , 2013 , 21, 3497-507	3.9	68
199	Acceptance of transvaginal sonography by postmenopausal women participating in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013 , 41, 73-9	5.8	15
198	Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. <i>Lancet Oncology, The</i> , 2013 , 14, 962-70	21.7	143
197	International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. <i>Breast</i> , 2013 , 22, 203-10	3.6	66
196	Drivers and barriers to patient participation in RCTs. <i>British Journal of Cancer</i> , 2013 , 108, 1402-7	8.7	59
195	Teams Talking Trials: results of an RCT to improve the communication of cancer teams about treatment trials. <i>Contemporary Clinical Trials</i> , 2013 , 35, 43-51	2.3	16
194	Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. <i>Cancer</i> , 2013 , 119, 832-8	6.4	106
193	ARIX: a randomised trial of acupuncture v oral care sessions in patients with chronic xerostomia following treatment of head and neck cancer. <i>Annals of Oncology</i> , 2013 , 24, 776-83	10.3	67
192	Adjuvant chemotherapy in elderly women with breast cancer (AChEW): an observational study identifying MDT perceptions and barriers to decision making. <i>Annals of Oncology</i> , 2013 , 24, 1211-9	10.3	29
191	Adjuvant chemotherapy in elderly women with breast cancer: patients' perspectives on information giving and decision making. <i>Psycho-Oncology</i> , 2013 , 22, 2729-35	3.9	28
190	Patients' and oncologists' views on the treatment and care of advanced ovarian cancer in the U.K.: results from the ADVOCATE study. <i>British Journal of Cancer</i> , 2013 , 108, 2264-71	8.7	25
189	Randomized controlled trial of pulmonary metastasectomy in colorectal cancer: PulMiCC International is open in Italy. <i>Oncologist</i> , 2013 , 18, 637	5.7	5
188	1st International consensus guidelines for advanced breast cancer (ABC 1). <i>Breast</i> , 2012 , 21, 242-52	3.6	258
187	Group recruitment sessions enhance patient understanding in a small multi-centre phase III clinical trial. <i>Contemporary Clinical Trials</i> , 2012 , 33, 286-90	2.3	5
186	Specialist breast care and research nurses' attitudes to adjuvant chemotherapy in older women with breast cancer. <i>European Journal of Oncology Nursing</i> , 2012 , 16, 78-86	2.8	2
185	Time for a low-risk DCIS trial: harnessing public and patient involvement. <i>Lancet Oncology, The</i> , 2012 , 13, 1183-5	21.7	13
184	Patient-reported outcome instruments used to assess pain and functioning in studies of bisphosphonate treatment for bone metastases. <i>Supportive Care in Cancer</i> , 2012 , 20, 657-77	3.9	15

183	Pulmonary metastasectomy in colorectal cancer: the PulMiCC trial. <i>Thorax</i> , 2012 , 67, 185-7	7.3	86
182	Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012 , 23 Suppl 7, vii11-9	10.3	356
181	Evaluation of an educational program to improve communication with patients about early-phase trial participation. <i>Oncologist</i> , 2012 , 17, 377-83	5.7	25
180	Supportive follow-up in patients treated with radical intent for high-grade glioma. <i>CNS Oncology</i> , 2012 , 1, 39-48	4	6
179	Systematic review of supportive care needs in patients with primary malignant brain tumors. <i>Neuro-Oncology</i> , 2012 , 14, 392-404	1	129
178	Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation. <i>British Journal of Cancer</i> , 2012 , 106, 1062-7	8.7	40
177	Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. <i>Clinical Cancer Research</i> , 2012 , 18, 4841-9	12.9	102
176	Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. <i>Annals of Oncology</i> , 2012 , 23, 3045-3051	10.3	42
175	ARIX: A randomized trial of acupuncture versus oral care sessions in patients with chronic radiation-induced xerostomia following treatment for head and neck cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 5527-5527	2.2	
174	Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials. <i>Trials</i> , 2011 , 12, 61	2.8	32
173	Reasons given by patients for participating, or not, in Phase 1 cancer trials. <i>European Journal of Cancer</i> , 2011 , 47, 1490-7	7.5	54
172	Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. <i>Lancet Oncology, The</i> , 2011 , 12, 38-48	21.7	138
171	Discussing expensive anti-cancer drugs. <i>British Journal of Health Care Management</i> , 2011 , 17, 206-212	0.4	3
170	The views of patients and the general public about expensive anti-cancer drugs in the NHS: a questionnaire-based study. <i>JRSM Short Reports</i> , 2011 , 2, 69		8
169	Breast cancer screening review. What should women do in the meantime?. <i>BMJ, The</i> , 2011 , 343, d7544	5.9	2
168	A UK-wide survey of follow-up practices for patients with high-grade glioma treated with radical intent. <i>Journal of Evaluation in Clinical Practice</i> , 2011 , 17, 1-6	2.5	10
167	Clinicians' attitudes towards clinical trials of cancer therapy. <i>British Journal of Cancer</i> , 2011 , 104, 1535-43	3.7	35
166	Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability. <i>Breast Cancer Research and Treatment</i> , 2011 , 125, 741-9	4.4	14

165	The preferences and experiences of different bisphosphonate treatments in women with breast cancer. <i>Psycho-Oncology</i> , 2011 , 20, 755-61	3.9	7
164	Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2011 , 22 Suppl 6, vi25-30	10.3	75
163	What oncologists believe they said and what patients believe they heard: an analysis of phase I trial discussions. <i>Journal of Clinical Oncology</i> , 2011 , 29, 61-8	2.2	108
162	Adjuvant chemotherapy in older women (ACTION) study - what did we learn from the pilot phase?. <i>British Journal of Cancer</i> , 2011 , 105, 1260-6	8.7	41
161	The treatment of early breast cancer in women over the age of 70. <i>British Journal of Cancer</i> , 2011 , 105, 189-93	8.7	43
160	The value of progression-free survival to patients with advanced-stage cancer. <i>Nature Reviews Clinical Oncology</i> , 2011 , 9, 41-7	19.4	46
159	Awareness of ovarian cancer risk factors, beliefs and attitudes towards screening: baseline survey of 21,715 women participating in the UK Collaborative Trial of Ovarian Cancer Screening. <i>British Journal of Cancer</i> , 2010 , 103, 454-61	8.7	25
158	The attitudes of 1066 patients with cancer towards participation in randomised clinical trials. <i>British Journal of Cancer</i> , 2010 , 103, 1801-7	8.7	64
157	Communication skills training in oncology: a position paper based on a consensus meeting among European experts in 2009. <i>Annals of Oncology</i> , 2010 , 21, 204-207	10.3	121
156	Communication with patients after errors. <i>Journal of Health Services Research and Policy</i> , 2010 , 15 Suppl 1, 56-9	2.4	11
155	Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010 , 21 Suppl 5, v15-9	10.3	92
154	Living with metastatic breast cancer: a global patient survey. <i>Community Oncology</i> , 2010 , 7, 406-412		19
153	Pulmonary metastasectomy in colorectal cancer: the PulMiCC trial. <i>Journal of Thoracic Oncology</i> , 2010 , 5, S203-6	8.9	75
152	Communication and informed consent in phase 1 trials: a review of the literature from January 2005 to July 2009. <i>Supportive Care in Cancer</i> , 2010 , 18, 1115-21	3.9	25
151	A Rasch and confirmatory factor analysis of the general health questionnaire (GHQ)--12. <i>Health and Quality of Life Outcomes</i> , 2010 , 8, 45	3	36
150	International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 1174-81	9.7	177
149	Group acupuncture to relieve radiation induced xerostomia: a feasibility study. <i>Acupuncture in Medicine</i> , 2009 , 27, 109-13	1.9	22
148	Quality of life and patient-reported outcomes in the older breast cancer patient. <i>Clinical Oncology</i> , 2009 , 21, 140-55	2.8	19

147	Pulmonary metastasectomy in colorectal cancer: time for a trial. <i>European Journal of Surgical Oncology</i> , 2009 , 35, 686-9	3.6	38
146	Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Lancet Oncology, The</i> , 2009 , 10, 327-40	21.7	615
145	The challenge of interacting with patients in oncology. <i>European Journal of Cancer</i> , 2009 , 45 Suppl 1, 445-6	7.5	9
144	Quality of life issues during adjuvant endocrine therapy. <i>Cancer Treatment and Research</i> , 2009 , 151, 353-65	9.5	2
143	Rasch fit statistics and sample size considerations for polytomous data. <i>BMC Medical Research Methodology</i> , 2008 , 8, 33	4.7	181
142	Which bisphosphonates do oncologists prescribe for women with metastatic breast cancer and why? Results of a UK survey. <i>Breast</i> , 2008 , 17, 459-63	3.6	4
141	Patients' decision-making in a UK specialist centre with high mastectomy rates. <i>Breast</i> , 2008 , 17, 574-9	3.6	17
140	Psychosocial aspects of risk appraisal. <i>Breast Cancer Research</i> , 2008 , 10 Suppl 4, S14	8.3	4
139	Adherence to hormone therapy in a chemoprevention randomised trial. <i>Breast Cancer Research</i> , 2008 , 10,	8.3	78
138	Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). <i>Lancet Oncology, The</i> , 2008 , 9, 953-61	21.7	101
137	Psychosocial and supportive-care needs in high-grade glioma. <i>Lancet Oncology, The</i> , 2008 , 9, 884-91	21.7	135
136	Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. <i>Lancet Oncology, The</i> , 2008 , 9, 1143-8	21.7	150
135	Patient-physician interactions during early breast-cancer treatment: results from an international online survey. <i>Current Medical Research and Opinion</i> , 2008 , 24, 1891-904	2.5	15
134	There's many a slip twixt cup and lip: adherence issues in cancer therapy. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 118-9		12
133	Recruitment to multicentre trials--lessons from UKCTOCS: descriptive study. <i>BMJ, The</i> , 2008 , 337, a20795.9	5.9	105
132	Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2008 , 107, 167-80	4.4	185
131	Treatment decision-making in breast cancer: the patient-doctor relationship. <i>Breast Cancer Research and Treatment</i> , 2008 , 112 Suppl 1, 5-13	4.4	137
130	Sun-protective behaviors in families at increased risk of melanoma. <i>Journal of Investigative Dermatology</i> , 2007 , 127, 1343-50	4.3	13

129	The quality of life of men with locally advanced prostate cancer during neoadjuvant hormone therapy: data from the Medical Research Council RT01 trial (ISRCTN 47772397). <i>BJU International</i> , 2007 , 99, 301-10	5.6	24
128	Psychosexual function and impact of gynaecological cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2007 , 21, 309-20	4.6	50
127	Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial. <i>British Journal of Cancer</i> , 2007 , 97, 152-61	8.7	46
126	Fallowfield's Sexual Activity Questionnaire in women with without and at risk of cancer. <i>Menopause International</i> , 2007 , 13, 103-9		26
125	Does endocrine therapy for the treatment and prevention of breast cancer affect memory and cognition?. <i>European Journal of Cancer</i> , 2007 , 43, 1342-7	7.5	28
124	After going through chemotherapy I can't see another needle. <i>European Journal of Oncology Nursing</i> , 2007 , 11, 43-8	2.8	30
123	Quality of life issues in relation to the aromatase inhibitor. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007 , 106, 168-72	5.1	16
122	Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. <i>Lancet, The</i> , 2007 , 369, 559-70	4.0	712
121	Why patient recorded outcomes should be mandatory in and outside clinical trials to guide management of patients with metastatic breast cancer. <i>Breast Cancer Research</i> , 2007 , 9,	8.3	2
120	Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. <i>Annals of Oncology</i> , 2006 , 17, 205-10	10.3	128
119	Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 599-609	9.7	1177
118	Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 910-7	2.2	159
117	Multidisciplinary teams in cancer care: are they effective in the UK?. <i>Lancet Oncology, The</i> , 2006 , 7, 935-43	11.7	415
116	Intentional and non-intentional non-adherence to medication amongst breast cancer patients. <i>European Journal of Cancer</i> , 2006 , 42, 2271-6	7.5	278
115	Information provision for patients by breast cancer teams about the side-effects of hormone treatments. <i>European Journal of Cancer</i> , 2006 , 42, 1760-7	7.5	13
114	Information needs and experiences: an audit of UK cancer patients. <i>European Journal of Oncology Nursing</i> , 2006 , 10, 263-72	2.8	155
113	Postmenopausal women undergoing transvaginal ultrasound screening prefer not to have chaperones. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2006 , 113, 954-7	3.7	9
112	What non-prescription treatments do UK women with breast cancer use?. <i>European Journal of Cancer Care</i> , 2006 , 15, 279-85	2.4	14

111	Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2006 , 95, 279-93	4.4	360
110	Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2006 , 100, 273-84	4.4	191
109	Communication and informed consent in phase 1 trials: a review of the literature. <i>Supportive Care in Cancer</i> , 2006 , 14, 303-9	3.9	65
108	Current concepts of communication skills training in oncology. <i>Recent Results in Cancer Research</i> , 2006 , 168, 105-12	1.5	44
107	Preferences of healthy men for two different endocrine treatment options offered for locally advanced prostate cancer. <i>Current Medical Research and Opinion</i> , 2005 , 21, 1329-35	2.5	5
106	Health-related quality of life in patients undergoing drug therapy for advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2005 , 48, 365-77	5.9	19
105	Discussing randomised clinical trials of cancer therapy: evaluation of a Cancer Research UK training programme. <i>BMJ, The</i> , 2005 , 330, 400	5.9	59
104	The informational roles and psychological health of members of 10 oncology multidisciplinary teams in the UK. <i>British Journal of Cancer</i> , 2005 , 93, 1092-7	8.7	74
103	Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile?. <i>British Journal of Cancer</i> , 2005 , 93, 1319-23	8.7	40
102	Acceptance of adjuvant therapy and quality of life issues. <i>Breast</i> , 2005 , 14, 612-6	3.6	41
101	P126 Routes of administration in breast cancer:Preliminary findings from a patient survey. <i>Breast</i> , 2005 , 14, S51	3.6	2
100	The use of denial in an ethnically diverse British cancer population: a cross-sectional study. <i>British Journal of Cancer</i> , 2005 , 92, 1393-7	8.7	28
99	The preferences of 600 patients for different descriptions of randomisation. <i>British Journal of Cancer</i> , 2005 , 92, 807-10	8.7	11
98	Five-year quality of life (QOL) follow-up of adjuvant endocrine therapy for postmenopausal women in the Arimidex (A), Tamoxifen (T), Alone or in Combination (ATAC) Trial. <i>Journal of Clinical Oncology</i> , 2005 , 23, 577-577	2.2	15
97	A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. <i>New England Journal of Medicine</i> , 2004 , 350, 1081-92	59.2	1500
96	Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4261-71	2.2	243
95	Anxiety and support in breast cancer: is this different for affluent and deprived women? A questionnaire study. <i>British Journal of Cancer</i> , 2004 , 91, 879-83	8.7	24
94	Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. <i>Psycho-Oncology</i> , 2004 , 13, 61-6	3.9	180

93	Epoetin alfa improves quality of life in patients with cancer: results of metaanalysis. <i>Cancer</i> , 2004 , 101, 1720-32	6.4	77
92	Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. <i>Radiotherapy and Oncology</i> , 2004 , 72, 199-211	5.3	51
91	Same gain, less pain: potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer. <i>European Journal of Cancer</i> , 2004 , 40, 2403-10	7.5	37
90	Evolution of breast cancer treatments: current options and quality-of-life considerations. <i>European Journal of Oncology Nursing</i> , 2004 , 8 Suppl 2, S75-82	2.8	26
89	Sentinel lymph node biopsy in male breast cancer patients. <i>European Journal of Surgical Oncology</i> , 2004 , 30, 480-3	3.6	59
88	Communicating sad, bad, and difficult news in medicine. <i>Lancet, The</i> , 2004 , 363, 312-9	4.0	665
87	Doctors' communication of trust, care, and respect: details of paper were incorrect. <i>BMJ, The</i> , 2004 , 328, 1317-8; author reply 1319	5.9	2
86	Sentinel node biopsy in breast cancer: The first results of the randomized multicenter ALMANAC Trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 506-506	2.2	6
85	Sentinel node biopsy in breast cancer: The first results of the randomized multicenter ALMANAC Trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 506-506	2.2	4
84	Lack of communication between healthcare professionals and women with ovarian cancer about sexual issues. <i>British Journal of Cancer</i> , 2003 , 88, 666-71	8.7	249
83	A qualitative study looking at the psychosocial implications of bilateral prophylactic mastectomy. <i>Breast</i> , 2003 , 12, 1-9	3.6	49
82	Lay understanding of terms used in cancer consultations. <i>Psycho-Oncology</i> , 2003 , 12, 557-66	3.9	135
81	Factors affecting patient and clinician satisfaction with the clinical consultation: can communication skills training for clinicians improve satisfaction?. <i>Psycho-Oncology</i> , 2003 , 12, 599-611	3.9	127
80	The effects of hormone therapy on cognition in breast cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2003 , 86, 405-12	5.1	108
79	Enduring impact of communication skills training: results of a 12-month follow-up. <i>British Journal of Cancer</i> , 2003 , 89, 1445-9	8.7	253
78	Can communication skills training alter physicians' beliefs and behavior in clinics?. <i>Journal of Clinical Oncology</i> , 2002 , 20, 765-9	2.2	171
77	The psychological impact of post-operative arm morbidity following axillary surgery for breast cancer: a critical review. <i>Breast</i> , 2002 , 11, 81-7	3.6	26
76	The impact of endocrine therapy on patients with breast cancer: a review of the literature. <i>Breast</i> , 2002 , 11, 1-12	3.6	12

75	Quality of life: a new perspective for cancer patients. <i>Nature Reviews Cancer</i> , 2002 , 2, 873-9	31.3	76
74	Describing randomisation: patients' and the public's preferences compared with clinicians' practice. <i>British Journal of Cancer</i> , 2002 , 87, 854-8	8.7	32
73	Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. <i>British Journal of Cancer</i> , 2002 , 87, 1341-53	8.7	105
72	Truth may hurt but deceit hurts more: communication in palliative care. <i>Palliative Medicine</i> , 2002 , 16, 297-303	5.5	341
71	Efficacy of a Cancer Research UK communication skills training model for oncologists: a randomised controlled trial. <i>Lancet, The</i> , 2002 , 359, 650-6	4.0	634
70	Acronymic trials: the good, the bad, and the coercive. <i>Lancet, The</i> , 2002 , 360, 1622	4.0	7
69	What is newsworthy? Bad news from research really is headline news. <i>BMJ, The</i> , 2002 , 325, 774	5.9	2
68	The impact of hormone replacement therapy on breast cancer patients' quality of life and sexuality: a pilot study. <i>The Journal of the British Menopause Society</i> , 2001 , 7, 85-91		6
67	Communication about sexual problems and sexual concerns in ovarian cancer: qualitative study. <i>BMJ: British Medical Journal</i> , 2001 , 323, 836-7		86
66	The psychosocial impact of bilateral prophylactic mastectomy: prospective study using questionnaires and semistructured interviews. <i>BMJ: British Medical Journal</i> , 2001 , 322, 76		118
65	Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for 'well-tolerated' treatments?. <i>Breast Cancer Research and Treatment</i> , 2001 , 66, 73-81	4.4	82
64	The validation of a quality of life scale to assess the impact of arm morbidity in breast cancer patients post-operatively. <i>Breast Cancer Research and Treatment</i> , 2001 , 68, 273-82	4.4	118
63	The effects of oestrogens and anti-oestrogens on cognition. <i>Breast</i> , 2001 , 10, 484-91	3.6	31
62	Are members of multidisciplinary teams in breast cancer aware of each other's informational roles?. <i>Quality in Health Care: QHC</i> , 2001 , 10, 70-5		71
61	Information needs of patients with cancer: results from a large study in UK cancer centres. <i>British Journal of Cancer</i> , 2001 , 84, 48-51	8.7	566
60	Psychiatric morbidity and its recognition by doctors in patients with cancer. <i>British Journal of Cancer</i> , 2001 , 84, 1011-5	8.7	491
59	Results of an intervention study to improve communication about randomised clinical trials of cancer therapy. <i>European Journal of Cancer</i> , 2001 , 37, 322-31	7.5	52
58	Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1885-92	2.2	203

57	Teaching Senior Nurses How to Teach Communication Skills in Oncology. <i>Cancer Nursing</i> , 2001 , 24, 185-196		73
56	Teaching senior nurses how to teach communication skills in oncology. <i>Cancer Nursing</i> , 2001 , 24, 185-91	2.6	23
55	The Medical Interaction Process System (MIPS): an instrument for analysing interviews of oncologists and patients with cancer. <i>Social Science and Medicine</i> , 2000 , 50, 553-66	5.1	100
54	Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy. <i>British Journal of Cancer</i> , 2000 , 82, 1783-8	8.7	212
53	How to improve the communication skills of oncologists. <i>Annals of Oncology</i> , 2000 , 11 Suppl 3, 63-6	10.3	10
52	The psychological impact of immediate rather than delayed breast reconstruction. <i>European Journal of Surgical Oncology</i> , 2000 , 26, 17-9	3.6	327
51	Comparison of psychological aspects and patient satisfaction following breast conserving surgery, simple mastectomy and breast reconstruction. <i>European Journal of Cancer</i> , 2000 , 36, 1938-43	7.5	474
50	Clinical trials to real life: the relevance of quality of life. <i>Pharmaceutical Medicine</i> , 2000 , 14, 82-84		4
49	Sexual activity questionnaires in clinical trials: acceptability to patients with gynaecological disorders. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1999 , 106, 50-4	3.7	38
48	Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. <i>Breast Cancer Research and Treatment</i> , 1999 , 55, 189-99	4.4	242
47	Patient evaluation of cosmetic outcome after conserving surgery for treatment of primary breast cancer. <i>European Journal of Surgical Oncology</i> , 1999 , 25, 344-6	3.6	43
46	Does cosmetic outcome from treatment of primary breast cancer influence psychosocial morbidity?. <i>European Journal of Surgical Oncology</i> , 1999 , 25, 571-3	3.6	170
45	Are we using appropriate self-report questionnaires for detecting anxiety and depression in women with early breast cancer?. <i>European Journal of Cancer</i> , 1999 , 35, 79-85	7.5	137
44	Florence statement on breast cancer, 1998. <i>European Journal of Cancer</i> , 1999 , 35, 14-15	7.5	33
43	How do doctors explain randomised clinical trials to their patients?. <i>European Journal of Cancer</i> , 1999 , 35, 1187-93	7.5	89
42	Effective communication skills are the key to good cancer care. <i>European Journal of Cancer</i> , 1999 , 35, 1592-7	7.5	377
41	Positive epoetin alfa effect on quality of life in anemic cancer patients receiving chemotherapy: results from a randomized placebo-controlled trial. <i>European Journal of Cancer</i> , 1999 , 35, S360	7.5	3
40	Contraceptive use by women receiving chemotherapy for breast cancer. <i>Breast</i> , 1998 , 7, 143-149	3.6	8

39	Missing quality of life data in cancer clinical trials: serious problems and challenges. <i>Statistics in Medicine</i> , 1998 , 17, 517-32	2.3	162
38	Effect of early American results on patients in a tamoxifen prevention trial (IBIS). International Breast Cancer Intervention Study. <i>Lancet, The</i> , 1998 , 352, 1222	4.0	8
37	Attitudes of patients to randomised clinical trials of cancer therapy. <i>European Journal of Cancer</i> , 1998 , 34, 1554-9	7.5	99
36	Teaching senior oncologists communication skills: results from phase I of a comprehensive longitudinal program in the United Kingdom. <i>Journal of Clinical Oncology</i> , 1998 , 16, 1961-8	2.2	284
35	Sexuality in women receiving chemotherapy for breast cancer. <i>Annals of Oncology</i> , 1997 , 8, 616-8	10.3	5
34	Clinicians' attitudes to clinical trials of cancer therapy. <i>European Journal of Cancer</i> , 1997 , 33, 2221-9	7.5	98
33	Truth sometimes hurts but deceit hurts more. <i>Annals of the New York Academy of Sciences</i> , 1997 , 809, 525-36	6.5	43
32	Offering choice of surgical treatment to women with breast cancer. <i>Patient Education and Counseling</i> , 1997 , 30, 209-14	3.1	70
31	Quality of quality-of-life data. <i>Lancet, The</i> , 1996 , 348, 421-2	4.0	45
30	Doctor-patient interactions in oncology. <i>Social Science and Medicine</i> , 1996 , 42, 1511-9	5.1	310
29	The Sexual Activity Questionnaire: a measure of women's sexual functioning. <i>Quality of Life Research</i> , 1996 , 5, 81-90	3.7	257
28	Has Psychosocial Oncology Helped in the Management of Women with Breast Cancer?. <i>Breast Journal</i> , 1996 , 2, 107-113	1.2	11
27	When Breast Cancer Recurs: A 3-Year Prospective Study of Psychological Morbidity. <i>Breast Journal</i> , 1996 , 2, 197-203	1.2	24
26	Anxiety in women "at risk" of developing breast cancer. <i>British Journal of Cancer</i> , 1996 , 73, 1422-4	8.7	16
25	Things to consider when teaching doctors how to deliver good, bad and sad news. <i>Medical Teacher</i> , 1996 , 18, 27-30	3	15
24	Information needs of cancer patients in west Scotland: cross sectional survey of patients' views. <i>BMJ: British Medical Journal</i> , 1996 , 313, 724-6		390
23	No news is not good news: information preferences of patients with cancer. <i>Psycho-Oncology</i> , 1995 , 4, 197-202	3.9	190
22	Questionnaire design. <i>Archives of Disease in Childhood</i> , 1995 , 72, 76-9	2.2	16

21	Psychological morbidity in newly referred patients with cancer. <i>Journal of Psychosomatic Research</i> , 1995 , 39, 193-202	4.1	80
20	Assessment of quality of life in breast cancer. <i>Acta Oncologica</i> , 1995 , 34, 689-94	3.2	41
19	The efficacy of audiotapes in promoting psychological well-being in cancer patients: a randomised, controlled trial. <i>British Journal of Cancer</i> , 1995 , 71, 388-92	8.7	84
18	Quality of Life in the Elderly Woman with Breast Cancer Treated with Tamoxifen and Surgery or Tamoxifen Alone. <i>Journal of Womens Health</i> , 1994 , 3, 17-20		10
17	Information preferences of patients with cancer. <i>Lancet, The</i> , 1994 , 344, 1576	4.0	52
16	Can oncologists detect distress in their out-patients and how satisfied are they with their performance during bad news consultations?. <i>British Journal of Cancer</i> , 1994 , 70, 767-70	8.7	174
15	Communication and counselling needs of patients with lymphoma. <i>British Journal of Hospital Medicine</i> , 1994 , 52, 70-3		1
14	Delivering bad news in gastroenterology. <i>American Journal of Gastroenterology</i> , 1994 , 89, 473-9	0.7	13
13	Psychological effects of being offered choice of surgery for breast cancer. <i>BMJ: British Medical Journal</i> , 1994 , 309, 448		161
12	Giving sad and bad news. <i>Lancet, The</i> , 1993 , 341, 476-8	4.0	208
11	Quality of life in breast cancer--results from 3 cancer research campaign studies. <i>Acta Clinica Belgica</i> , 1993 , 15, 19-23	1.8	3
10	A daily diary for quality of life measurement in advanced breast cancer trials. <i>British Journal of Cancer</i> , 1993 , 67, 341-6	8.7	40
9	Evaluation of counselling in the National Health Service. <i>Journal of the Royal Society of Medicine</i> , 1993 , 86, 429-30	2.3	1
8	Quality of life measurement in breast cancer. <i>Journal of the Royal Society of Medicine</i> , 1993 , 86, 10-2	2.3	6
7	Cancer counselling in the United Kingdom. <i>Psychology and Health</i> , 1992 , 6, 107-117	2.9	11
6	The ideal consultation. <i>British Journal of Hospital Medicine</i> , 1992 , 47, 364-7		11
5	Psychological outcomes of different treatment policies in women with early breast cancer outside a clinical trial. <i>BMJ: British Medical Journal</i> , 1990 , 301, 575-80		566
4	What are the psychological factors influencing attendance, non-attendance and re-attendance at a breast screening centre?. <i>Journal of the Royal Society of Medicine</i> , 1990 , 83, 547-51	2.3	22

- 3 Psychological outcome of treatment for early breast cancer: A review. *Stress and Health*, **1989**, 5, 167-175 27
- 2 Counselling for patients with cancer. *BMJ: British Medical Journal*, **1988**, 297, 727-8 36
- 1 Effects of breast conservation on psychological morbidity associated with diagnosis and treatment of early breast cancer. *British Medical Journal*, **1986**, 293, 1331-4 254